Puente J, Calderero V, García-Muro X, Trigo JM, Castro AJ, Martín-Escudero V, Yébenes M, Casado MA
Costs of adverse events management associated to the treatment of first-line metastatic renal cell carcinoma with bevacizumab + interferon alpha-2a compared with sunitinib in Spain
34th Congress of the European Society for Medical Oncology (ESMO). Berlin, Germany. 20-24 sep 2009
Oyagüez I, Casado MA, Cotarelo M, Ramírez-Arellano A, Mallolas J
Impacto presupuestario de una combinación a dosis fija de efavirenz-emtricitabina-tenofovir para tratamiento de pacientes infectados por el virus de la inmunodeficiencia humana tipo 1
Farm Hosp. 2009;33:247-56
Buti M, Wong J, Casado MA, Esteban R
Modeling the cost-effectiveness of different oral antiviral therapies in patients with chronic hepatitis B
J Hepatol. 2009;51:640-6
Casado MA, Brosa M, Buti M
Some oral antivirals are more cost-effective than others for the treatment of chronic hepatitis B
J Hepatol. 2009;51:1087-8
Taxonera C, Calvet X, Gisbert JP, Rodrigo L, Bujanda L, Muñoz F, Ponce M, Gómez-Camacho F, Oyagüez I, Díaz-Rubio M, on behalf of COSCOL investigators
Unexpected follow-up surgeries related to failures in colectomy for ulcerative colitis
Digestive Disease Week (DDW). Chicago, Illinois. 30 may-4 jun 2009
Taxonera C, Calvet X, Gisbert JP, Rodrigo L, Bujanda L, Muñoz F, Ponce M, Gómez-Camacho F, Mendoza JL, Oyagüez I, Sabater FJ, on behalf of COSCOL study investigators